Comparison of Effects of Alendronate and Raloxifene on Lumbar Bone Mineral Density, Bone Turnover, and Lipid Metabolism in Elderly Women with Osteoporosis

키워드

참고문헌 (32)

1. Ensrud KE, "Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass", J Am Geriatr, 48, pp.241~249 (2000)
2. Kanis JA, "The components of excess mortality after hip fracture", Bone, 32, pp.468~473 (2003)
3. Cranney A, "Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis", Endocr Rev, 23, pp.570~578 (2002)
4. Papapoulos SE, "Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women", Osteoporos Int, 16, pp.468~474 (2005)
5. Siris ES, "Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study", J Bone Miner Res, 20, pp.1514~1524 (2005)
6. Bone HG, "Ten years' experience with alendronate for osteoporosis in postmenopausal women", N Engl J Med, 350, pp.1189~1199 (2004)
7. Liberman UA, "Hip and non-spine fracture risk reductions differ among antiresorptive agents: Evidence from randomised controlled trials", Int J Clin Pract, 60, pp.1394~1400 (2006)
8. Ettinger B, "Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial", JAMA, 282, pp.637~645 (1999)
9. Cummings SR, "Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial", JAMA, 280, pp.2077~2082 (1998)
10. Black DM, "Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures", Lancet, 348, pp.15353~1541 (1996)
11. Delmas PD, "Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women", N Engl J Med, 337, pp.1641~1647 (1997)
12. Orimo H, "Diagnostic criteria of primary osteoporosis", J Bone Miner Metab, 16, pp.139~150 (1998)
13. Orimo H, "Diagnostic criteria for primary osteoporosis: year 2000 revision", J Bone Miner Metab, 19, pp.331~337 (2001)
14. Shiraki M, "A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis", Osteoporos Int, 10, pp.183~192 (1999)
15. Kushida K, "The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: a randomized, double-blind, active-controlled, double-dummy trial", Current Therapeutic Research, 63(9), pp.606~620 (2002)
16. Morii H, "Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo- controlled trial", Osteoporos Int, 14, pp.793~800 (2003)
17. Sambrook PN, "Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International", J Intern Med, 255, pp.503~511 (2004)
18. Iwamoto J, "Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis", J Bone Miner Metab, 23, pp.238~242 (2005)
19. Garnero P, "Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment", J Clin Endocrinol Metab, 79, pp.1693~1700 (1994)
20. Greenspan SL, "Early changes in biochemical markers of bone turnover predict the long- term response to alendronate therapy in representative elderly women: a randomized clinical trial", J Bone Miner Res, 13, pp.1431~1438 (1998)
21. Tonino RP, "Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group", J Clin Endocrinol Metab, 85, pp.3109~3115 (2000)
22. Rogers MJ, "Molecular mechanism of action of bisphosphonates", Bone, 24(5), pp.73s~79s (1999)
23. Nakamura T, "Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosis", J Bone Miner Metab, 24, pp.414~418 (2006)
24. Lufkin EG, "Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial", Curr Med Res Opin, 20, pp.351~357 (2004)
25. Cummings SR, "Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs", Am J Med, 112, pp.281~289 (2002)
26. Hochberg MC, "Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents", J Clin Endocrinol Metab, 87, pp.1586~1592 (2002)
27. Epstein S, "The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy", Mayo Clin Proc, 80, pp.379~388 (2005)
28. Cryer B, "Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?", Mayo Clin Proc, 77, pp.1031~1043 (2002)
29. Nishizawa Y, "Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004)", J Bone Miner Metab, 23, pp.97~104 (2005)
30. Kung AW, "Efficacy and safety of raloxifene 60mg", day in postmenopausal Asian women, 2003, pp.88, 3130~3136
31. Martino S, "Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene", J Natl Cancer Inst, 96, pp.1751~1761 (2004)
32. Barrett-Connor E, "Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women", N Engl J Med, 355, pp.125~137 (2006)

관련 논문AI추천